JACI In Practice:张清玲教授课题组发文,发现急性发作恢复期的哮喘存在不同表型

2018-05-19 张清玲、谢佳星 呼吸界

哮喘是一类具有明显异质性的疾病,而哮喘的不稳定性容易导致急性发作。因为急性发作恢复期哮喘患者的炎症和肺功能的严重程度更加突出,因此,急性发作恢复期哮喘患者的临床数据所获得的表型与稳定期哮喘患者所描述的不同。然而,目前对于急性发作恢复期的哮喘患者的肺功能和气道炎症加重的表型分析的研究极少。

近日,美国过敏、哮喘与免疫学学会(AAAAI)网站刊登了「急性发作恢复期的哮喘存在不同表型」的通讯稿。

该通讯稿指出,哮喘是一类具有明显异质性的疾病,而哮喘的不稳定性容易导致急性发作。因为急性发作恢复期哮喘患者的炎症和肺功能的严重程度更加突出,因此,急性发作恢复期哮喘患者的临床数据所获得的表型与稳定期哮喘患者所描述的不同。然而,目前对于急性发作恢复期的哮喘患者的肺功能和气道炎症加重的表型分析的研究极少。

近来,AAAAI旗下的JACI inPractice杂志发表了呼吸疾病国家重点实验室张清玲教授课题组的研究论文「哮喘急性发作恢复期表型研究Asthma phenotypes defined from parameters obtained during recovery from a hospital-treated exacerbation」。该研究回顾性分析了就诊于广州呼吸健康研究院的320例哮喘患者急性发作恢复期的临床指标,并对218例临床数据完整患者的13个临床指标进行了聚类分析。通过利用无监督的分层聚类分析方法研究急性发作恢复期的哮喘患者的人口学、不同气道炎症表型与肺功能特征,从而得出4个不同的哮喘亚型。

亚型1和亚型3主要是嗜中粒细胞型气道炎症为特征的女性患者,其中亚型1与轻度的阻塞性肺通气功能障碍和早发型哮喘有关,而亚型3与中度的阻塞性肺通气功能障碍有关;

亚型2和亚型4主要以嗜酸粒细胞型的气道炎症和重度阻塞性肺通气功能障碍为特征,其中亚型2以极重度阻塞性肺通气功能障碍的非吸烟女性哮喘患者为主,而亚型4以吸烟的男性哮喘患者为主。

对于过敏状态、血IgE、鼻部疾病、吸入糖皮质激素的剂量和全身糖皮质激素的使用,4个哮喘亚型之间不存在差异。

嗜酸粒细胞型或嗜中性粒细胞型气道炎症伴有不同程度的气流受限是区分急性发作恢复期哮喘不同亚型的基础。存在严重气流受限的吸烟或非吸烟哮喘急性发作恢复期患者均存在嗜酸粒细胞型气道炎症。本研究通过描述急性发作恢复期的哮喘患者的聚类分析特征可能对这些不同急性加重表型的哮喘患者的个体化治疗有很大帮助。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1953036, encodeId=cebe195303680, content=<a href='/topic/show?id=bafc5283ed3' target=_blank style='color:#2F92EE;'>#恢复期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52837, encryptionId=bafc5283ed3, topicName=恢复期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Wed Dec 19 00:17:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084041, encodeId=63ad2084041e4, content=<a href='/topic/show?id=29091460e26' target=_blank style='color:#2F92EE;'>#practice#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14607, encryptionId=29091460e26, topicName=practice)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Nov 22 14:17:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535174, encodeId=e88115351e4fd, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554305, encodeId=a0e51554305a8, content=<a href='/topic/show?id=8402522319e' target=_blank style='color:#2F92EE;'>#急性发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52231, encryptionId=8402522319e, topicName=急性发作)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=287314518946, createdName=anminleiryan, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316832, encodeId=fcfd31683298, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 20 07:23:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316808, encodeId=11843168080f, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Sun May 20 06:54:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316688, encodeId=738a3166886e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:21:49 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-12-19 by2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1953036, encodeId=cebe195303680, content=<a href='/topic/show?id=bafc5283ed3' target=_blank style='color:#2F92EE;'>#恢复期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52837, encryptionId=bafc5283ed3, topicName=恢复期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Wed Dec 19 00:17:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084041, encodeId=63ad2084041e4, content=<a href='/topic/show?id=29091460e26' target=_blank style='color:#2F92EE;'>#practice#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14607, encryptionId=29091460e26, topicName=practice)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Nov 22 14:17:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535174, encodeId=e88115351e4fd, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554305, encodeId=a0e51554305a8, content=<a href='/topic/show?id=8402522319e' target=_blank style='color:#2F92EE;'>#急性发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52231, encryptionId=8402522319e, topicName=急性发作)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=287314518946, createdName=anminleiryan, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316832, encodeId=fcfd31683298, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 20 07:23:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316808, encodeId=11843168080f, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Sun May 20 06:54:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316688, encodeId=738a3166886e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:21:49 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-11-22 heli0118
  3. [GetPortalCommentsPageByObjectIdResponse(id=1953036, encodeId=cebe195303680, content=<a href='/topic/show?id=bafc5283ed3' target=_blank style='color:#2F92EE;'>#恢复期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52837, encryptionId=bafc5283ed3, topicName=恢复期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Wed Dec 19 00:17:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084041, encodeId=63ad2084041e4, content=<a href='/topic/show?id=29091460e26' target=_blank style='color:#2F92EE;'>#practice#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14607, encryptionId=29091460e26, topicName=practice)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Nov 22 14:17:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535174, encodeId=e88115351e4fd, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554305, encodeId=a0e51554305a8, content=<a href='/topic/show?id=8402522319e' target=_blank style='color:#2F92EE;'>#急性发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52231, encryptionId=8402522319e, topicName=急性发作)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=287314518946, createdName=anminleiryan, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316832, encodeId=fcfd31683298, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 20 07:23:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316808, encodeId=11843168080f, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Sun May 20 06:54:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316688, encodeId=738a3166886e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:21:49 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-21 tastas
  4. [GetPortalCommentsPageByObjectIdResponse(id=1953036, encodeId=cebe195303680, content=<a href='/topic/show?id=bafc5283ed3' target=_blank style='color:#2F92EE;'>#恢复期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52837, encryptionId=bafc5283ed3, topicName=恢复期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Wed Dec 19 00:17:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084041, encodeId=63ad2084041e4, content=<a href='/topic/show?id=29091460e26' target=_blank style='color:#2F92EE;'>#practice#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14607, encryptionId=29091460e26, topicName=practice)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Nov 22 14:17:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535174, encodeId=e88115351e4fd, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554305, encodeId=a0e51554305a8, content=<a href='/topic/show?id=8402522319e' target=_blank style='color:#2F92EE;'>#急性发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52231, encryptionId=8402522319e, topicName=急性发作)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=287314518946, createdName=anminleiryan, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316832, encodeId=fcfd31683298, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 20 07:23:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316808, encodeId=11843168080f, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Sun May 20 06:54:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316688, encodeId=738a3166886e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:21:49 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1953036, encodeId=cebe195303680, content=<a href='/topic/show?id=bafc5283ed3' target=_blank style='color:#2F92EE;'>#恢复期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52837, encryptionId=bafc5283ed3, topicName=恢复期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Wed Dec 19 00:17:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084041, encodeId=63ad2084041e4, content=<a href='/topic/show?id=29091460e26' target=_blank style='color:#2F92EE;'>#practice#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14607, encryptionId=29091460e26, topicName=practice)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Nov 22 14:17:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535174, encodeId=e88115351e4fd, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554305, encodeId=a0e51554305a8, content=<a href='/topic/show?id=8402522319e' target=_blank style='color:#2F92EE;'>#急性发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52231, encryptionId=8402522319e, topicName=急性发作)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=287314518946, createdName=anminleiryan, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316832, encodeId=fcfd31683298, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 20 07:23:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316808, encodeId=11843168080f, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Sun May 20 06:54:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316688, encodeId=738a3166886e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:21:49 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-20 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1953036, encodeId=cebe195303680, content=<a href='/topic/show?id=bafc5283ed3' target=_blank style='color:#2F92EE;'>#恢复期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52837, encryptionId=bafc5283ed3, topicName=恢复期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Wed Dec 19 00:17:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084041, encodeId=63ad2084041e4, content=<a href='/topic/show?id=29091460e26' target=_blank style='color:#2F92EE;'>#practice#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14607, encryptionId=29091460e26, topicName=practice)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Nov 22 14:17:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535174, encodeId=e88115351e4fd, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554305, encodeId=a0e51554305a8, content=<a href='/topic/show?id=8402522319e' target=_blank style='color:#2F92EE;'>#急性发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52231, encryptionId=8402522319e, topicName=急性发作)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=287314518946, createdName=anminleiryan, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316832, encodeId=fcfd31683298, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 20 07:23:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316808, encodeId=11843168080f, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Sun May 20 06:54:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316688, encodeId=738a3166886e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:21:49 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-20 张新亮1853311252142e2fm

    好文献学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1953036, encodeId=cebe195303680, content=<a href='/topic/show?id=bafc5283ed3' target=_blank style='color:#2F92EE;'>#恢复期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52837, encryptionId=bafc5283ed3, topicName=恢复期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Wed Dec 19 00:17:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084041, encodeId=63ad2084041e4, content=<a href='/topic/show?id=29091460e26' target=_blank style='color:#2F92EE;'>#practice#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14607, encryptionId=29091460e26, topicName=practice)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Nov 22 14:17:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535174, encodeId=e88115351e4fd, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554305, encodeId=a0e51554305a8, content=<a href='/topic/show?id=8402522319e' target=_blank style='color:#2F92EE;'>#急性发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52231, encryptionId=8402522319e, topicName=急性发作)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=287314518946, createdName=anminleiryan, createdTime=Mon May 21 12:17:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316832, encodeId=fcfd31683298, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 20 07:23:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316808, encodeId=11843168080f, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Sun May 20 06:54:27 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316688, encodeId=738a3166886e, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:21:49 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-19 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

相关资讯

Semin Arthritis Rheu:女性类风湿性关节炎和COPD、哮喘的发病风险

在这项前瞻性队列研究中,RA与偶发性COPD风险升高相关,与生活方式混杂因素和包括吸烟在内的诊断后介质无关。

JAMA:对于持续性哮喘患者,LAMA 是ICS的得力助手吗?

2018年4月,发表在《JAMA》的一项由美国科学家进行的系统评价和Meta分析,考察了未控制的持续性哮喘患者中,吸入性糖皮质激素(ICS)和长效毒蕈碱受体拮抗剂(LAMA)与哮喘控制的相关性。

哮喘是世界第二致死致残疾病 我国控制率仅为28.3%

“哮喘是慢性疾病,很难彻底根治。在管理哮喘的过程中,专科医生只能起到20%的作用,剩下的80%需要患者自己完成。”近日,在中国哮喘联盟召开的2018世界哮喘日新闻发布会上,中国哮喘联盟总负责人、国务院政府特殊津贴享受者、中日友好医院呼吸内科主任林江涛一句话总结了患者在管理哮喘过程中的重要作用。

专家建议:控制哮喘是场持久战,要学会与哮喘病“和平共处”

2018年5月1日是第二十个“世界哮喘日”,今年哮喘日的主题是“重视气道疾病防治:从现在开始”。

JAMA:持续性哮喘患者 哪种治疗方案能防止哮喘加重?

2018年4月,发表于《JAMA》上的一项系统评价和Meta分析,考察了吸入性糖皮质激素和长效β-受体激动剂(LABA)作为控制治疗和快速缓解治疗与持续性哮喘患者哮喘加重和症状控制的相关性。

NEJM:按需吸入布地奈德-福莫特罗治疗轻度哮喘

研究认为,对于轻微哮喘人群,按需吸入布地奈德-福莫特罗对哮喘的控制效果优于特布他林,但劣于布地奈德维持治疗。含布地奈德治疗方案患者哮喘年度恶化率相近,且低于特布他林。布地奈德-福莫特罗方案的激素摄入量低于布地奈德维持治疗